The centre is expected to be fully operational by early 2008, employ more than 30 scientists and be equipped with state-of-the-art technology. The new Singapore venture is Qiagen’s latest step in the expansion of its presence in the rapidly growing Asian markets.
Peer Schatz, CEO of Qiagen, said: “The in-depth expertise and talent pool in biomedical research makes Singapore an ideal location for a centre for assay development.”